| FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer T Conroy, F Desseigne, M Ychou, O Bouché, R Guimbaud, Y Bécouarn, ... New England Journal of Medicine 364 (19), 1817-1825, 2011 | 4737 | 2011 |
| Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations LV Sequist, JCH Yang, N Yamamoto, K O'Byrne, V Hirsh, T Mok, ... Journal of clinical oncology 31 (27), 3327-3334, 2013 | 2496 | 2013 |
| Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised … JCH Yang, YL Wu, M Schuler, M Sebastian, S Popat, N Yamamoto, ... The lancet oncology 16 (2), 141-151, 2015 | 1132 | 2015 |
| Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial J Bennouna, J Sastre, D Arnold, P Österlund, R Greil, E Van Cutsem, ... The lancet oncology 14 (1), 29-37, 2013 | 973 | 2013 |
| Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer E Van Cutsem, WL Vervenne, J Bennouna, Y Humblet, S Gill, ... Journal of clinical oncology 27 (13), 2231-2237, 2009 | 666 | 2009 |
| Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial E Quoix, G Zalcman, JP Oster, V Westeel, E Pichon, A Lavolé, J Dauba, ... The Lancet 378 (9796), 1079-1088, 2011 | 536 | 2011 |
| Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study HL Kindler, T Ioka, DJ Richel, J Bennouna, R Létourneau, T Okusaka, ... The lancet oncology 12 (3), 256-262, 2011 | 353 | 2011 |
| Results of a phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non-small … G Robinet, P Thomas, JL Breton, H Lena, S Gouva, G Dabouis, ... Annals of oncology 12 (1), 59-67, 2001 | 287 | 2001 |
| Vγ9Vδ2 T cell response to colon carcinoma cells M Corvaisier, A Moreau-Aubry, E Diez, J Bennouna, JF Mosnier, E Scotet, ... The Journal of Immunology 175 (8), 5481-5488, 2005 | 240 | 2005 |
| LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung … JCH Yang, MH Schuler, N Yamamoto, KJ O'Byrne, V Hirsh, T Mok, ... Journal of Clinical Oncology 30 (18_suppl), LBA7500-LBA7500, 2012 | 234 | 2012 |
| Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non–small … LG Paz-Ares, B Biesma, D Heigener, J Von Pawel, T Eisen, J Bennouna, ... Journal of Clinical Oncology 30 (25), 3084-3092, 2012 | 227 | 2012 |
| Phase-I study of Innacell γδ™, an autologous cell-therapy product highly enriched in γ9δ2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma J Bennouna, E Bompas, EM Neidhardt, F Rolland, I Philip, C Galéa, ... Cancer immunology, immunotherapy 57 (11), 1599-1609, 2008 | 216 | 2008 |
| Aflibercept and docetaxel versus docetaxel alone after platinum failure in patients with advanced or metastatic non–small-cell lung cancer: a randomized, controlled phase III trial R Ramlau, V Gorbunova, TE Ciuleanu, S Novello, M Ozguroglu, T Goksel, ... Journal of Clinical Oncology 30 (29), 3640-3647, 2012 | 167 | 2012 |
| Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and … B Melichar, A Adenis, AC Lockhart, J Bennouna, EC Dees, O Kayaleh, ... The Lancet Oncology 16 (4), 395-405, 2015 | 159 | 2015 |
| Capecitabine plus oxaliplatin (XELOX) versus 5‐fluorouracil/leucovorin plus oxaliplatin (FOLFOX‐6) as first‐line treatment for metastatic colorectal cancer M Ducreux, J Bennouna, M Hebbar, M Ychou, G Lledo, T Conroy, ... International journal of cancer 128 (3), 682-690, 2011 | 159 | 2011 |
| NY-ESO-1 119–143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1-and Th2-type tumor-reactive CD4+ T cells HM Zarour, B Maillere, V Brusic, K Coval, E Williams, S Pouvelle-Moratille, ... Cancer Research 62 (1), 213-218, 2002 | 145 | 2002 |
| Randomized trial comparing a web-mediated follow-up with routine surveillance in lung cancer patients F Denis, C Lethrosne, N Pourel, O Molinier, Y Pointreau, J Domont, ... JNCI: Journal of the National Cancer Institute 109 (9), 2017 | 135 | 2017 |
| A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with … J Bennouna, I Lang, M Valladares-Ayerbes, K Boer, A Adenis, P Escudero, ... Investigational new drugs 29 (5), 1021-1028, 2011 | 131 | 2011 |
| T-cell–inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 … PA Ott, YJ Bang, SA Piha-Paul, ARA Razak, J Bennouna, JC Soria, ... Journal of Clinical Oncology 37 (4), 318-327, 2019 | 128 | 2019 |
| Safety and antitumor activity of the anti–programmed death-1 antibody pembrolizumab in patients with advanced esophageal carcinoma SA Piha-Paul, SI Jalal, S Saraf, J Lunceford, M Lunceford, J Bennouna ASCO, 2018 | 124 | 2018 |
